Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of Synflorix-vaccinated children with catch-up immunization in the sixth year of life
2007-005392-34Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2007
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of 10-valent pneumococcal conjugate vaccine in pneumococcal disease (2 arms), sponsored by GSK. Primary endpoints: Antibody persistence 1 year post-booster, Antibody persistence 2 years post-booster and 3 more. Started Dec 2007; status: completed.
02
Drugs
10-valent pneumococcal conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2007-005392-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005392-34.